Use of a pi3kα mutation-selective inhibitor

TW202631125APending Publication Date: 2026-08-01CHANGCHUN GENESCIENCE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
CHANGCHUN GENESCIENCE PHARM CO LTD
Filing Date
2025-09-10
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001070393_001
    Figure TWG2TA001070393_001
  • Figure TWG2TA001070393_002
    Figure TWG2TA001070393_002
  • Figure TWG2TA001070393_003
    Figure TWG2TA001070393_003
Patent Text Reader

Abstract

can inhibit the growth of HR-positive / HER2-negative breast cancer, colon cancer, and head and neck squamous cell carcinoma cells, and can be used in combination with a CDK4 / 6 inhibitor or a selective ER degrader, offering improved therapeutic efficacy and a favorable safety profile.
Need to check novelty before this filing date? Find Prior Art